Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Sutro Biopharma Stock Performance
NASDAQ:STRO opened at $7.09 on Friday. The stock has a market capitalization of $332.76 million, a PE ratio of -2.45 and a beta of 0.94. The business has a 50 day simple moving average of $5.32 and a two-hundred day simple moving average of $6.76. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.44 and a quick ratio of 5.90. Sutro Biopharma has a 1-year low of $3.33 and a 1-year high of $23.70.
Sutro Biopharma (NASDAQ:STRO - Get Rating) last announced its earnings results on Monday, August 8th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.09). Sutro Biopharma had a negative return on equity of 55.57% and a negative net margin of 252.33%. On average, research analysts predict that Sutro Biopharma will post -3.1 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on the company. JMP Securities reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Sutro Biopharma in a research note on Wednesday, July 6th. Wedbush cut their target price on Sutro Biopharma from $30.00 to $20.00 in a research report on Tuesday, May 10th. Piper Sandler increased their target price on Sutro Biopharma to $16.00 in a research report on Monday, July 4th. Finally, HC Wainwright cut their target price on Sutro Biopharma from $35.00 to $30.00 in a research report on Wednesday, May 11th.